Literature Monitoring for Pharmacovigilance: What the EMA Service Covers and What Remains Yours

Published literature is a source of safety information that companies are expected to screen. The EMA medical literature monitoring service removed a large part of the ICSR workload for many substances, but it did not remove the obligation to monitor.

What the EMA service does

Since September 2015 the EMA has screened selected medical literature for a defined list of active substances, around 400 substance groups, including herbal ones, and enters the resulting cases into EudraVigilance. For substances on that list, marketing authorisation holders do not resubmit the cases to EudraVigilance, and generally do not send them to national authorities. The Agency treats these cases as the holder’s own, so they count in the safety database and in aggregate reports.

What stays with you

The service is narrower than many assume. In practice, the holder remains responsible for:

  • Monitoring literature for substances that are not on the EMA list, and processing the resulting cases under normal timelines.
  • Screening sources the service does not cover, such as local-language and national journals.
  • Using literature in signal detection, risk management plans and periodic safety update reports, which the service does not do for you.
  • Reconciling its own records with the cases the service has created, including sending follow-up information that carries the Agency’s worldwide unique identifier where a duplicate arises.
  • Flagging cases where the service appears to have missed an article for a listed substance.

Designing a defensible search

Guidance gives weekly screening as an example frequency, and many holders adopt it. Whatever you choose, the search strategy should be documented and justified: databases, search terms covering the active substance and its synonyms, date limits, and the person responsible. A search that returns thousands of hits needs a documented triage step, and a search that returns nothing should be checked for whether the strategy is too narrow.

Case handling pitfalls

An article may describe several patients, and each patient with a valid case is a separate ICSR. The date of awareness is generally the date on which the company first became aware of the publication, not the publication date. Duplicates between literature cases and spontaneous reports of the same patient are common and must be linked rather than reported twice. Keep copies of the articles and the search records, because inspectors do ask for them.

How PQRA helps

PQRA can assess whether your literature monitoring strategy matches your product portfolio, help distinguish what is covered by the EMA service from what is not, and draft or review the procedures, search documentation and reconciliation checks. This matters most for older products and for portfolios mixing listed and non-listed substances.

Contact PQRA to discuss your pharmacovigilance system, in Greece and across the EU.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *